Key result
Targeted lifestyle changes and pharmacotherapy addressing modifiable risk factors such as lipid lowering, smoking cessation, and blood pressure control can reduce an individual's global CVD risk.
Why the study?
Does a comprehensive approach using lifestyle changes and pharmacotherapy reduce global risk for cardiovascular disease in symptomatic and asymptomatic patients?
Does a comprehensive approach using lifestyle changes and pharmacotherapy reduce global risk for cardiovascular disease in symptomatic and asymptomatic patients?
Comprehensive modification of major independent risk factors through lifestyle and pharmacotherapy is a key strategy for primary and secondary cardiovascular disease prevention.
Cardiovascular disease (CVD) is the leading cause of death and disability in industrialized societies, due in large part to the lack of a comprehensive approach to control the risk factors for atherosclerosis. One strategy for reducing an individual's global CVD risk relies on a targeted approach that modifies each of the major independent risk factors prevalent in both symptomatic (secondary prevention) and asymptomatic (primary prevention) patients. These interventions include lipid lowering, smoking cessation, blood pressure control, glycemic control, regular exercise, and the use of various medications. This review offers an evidence-based strategy toward reducing an individual's global risk for CVD by addressing the modifiable, major independent risk factors.
No takes yet. Share an insight, caveat, or question.
Cheng et al. (2002) conducted a review in Cardiovascular disease. Lifestyle changes and pharmacotherapy was evaluated. Targeted lifestyle changes and pharmacotherapy addressing modifiable risk factors such as lipid lowering, smoking cessation, and blood pressure control can reduce an individual's global CVD risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: